Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).

The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...

The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...

US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.